GID1 Gene

GID1 Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">GID1 — Glucose-Induced Degradation Deficient 1 Homolog</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>GID1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Glucose-Induced Degradation Deficient 1 Homolog</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>17p13.2</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/84144" target="_blank">84144</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000131791" target="_blank">ENSG00000131791</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/618023" target="_blank">618023</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q9NWV8" target="_blank">Q9NWV8</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td><a href="/diseases/huntington-disease">Huntington's Disease</a>, <a href="/diseases/spinocerebellar-ataxia">Spinocerebellar Ataxia</a>, <a href="/diseases/alzheimers-disease">Alzheimer's Disease</a></td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain, Liver, Kidney, Pancreas</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

GID1 — Glucose-Induced Degradation Deficient 1 Homolog

Introduction

GID1 Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">GID1 — Glucose-Induced Degradation Deficient 1 Homolog</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>GID1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Glucose-Induced Degradation Deficient 1 Homolog</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>17p13.2</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/84144" target="_blank">84144</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000131791" target="_blank">ENSG00000131791</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/618023" target="_blank">618023</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q9NWV8" target="_blank">Q9NWV8</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td><a href="/diseases/huntington-disease">Huntington's Disease</a>, <a href="/diseases/spinocerebellar-ataxia">Spinocerebellar Ataxia</a>, <a href="/diseases/alzheimers-disease">Alzheimer's Disease</a></td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain, Liver, Kidney, Pancreas</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

GID1 — Glucose-Induced Degradation Deficient 1 Homolog

Introduction

GID1 (Glucose-Induced Degradation Deficient 1 Homolog) is a critical component of the GID (CTLH) ubiquitin ligase complex, a multisubunit E3 ligase that plays essential roles in protein quality control, metabolic regulation, and cellular homeostasis. Originally discovered in yeast as a key regulator of gluconeogenesis, the GID complex has evolved to serve crucial functions in protein degradation pathways that are essential for neuronal health. Dysregulation of GID complex function has been increasingly implicated in neurodegenerative diseases, particularly Huntington's disease (HD), where alterations in protein homeostasis are a central pathological feature.

The GID complex represents an evolutionarily conserved system for targeted protein degradation, with homologs found from yeast to humans. In mammals, the complex has diversified to include additional subunits that regulate its activity and substrate specificity. This complexity allows for fine-tuned control over protein turnover in different cellular contexts, including post-mitotic neurons that are particularly vulnerable to proteostasis failures.

Gene Structure and Evolution

Evolutionary Conservation

The GID complex is highly conserved across eukaryotes:

• Yeast (S. cerevisiae): The GID complex (also called GID complex) consists of GID1, GID2, GID3, GID4, GID5, GID7, GID8, and GID9
• Mammals: The mammalian CTLH complex includes GID1 (also known as ARRDC1 or CT16), GID2, GID3, GID4, GID5, GID7, GID8, GID9, and additional subunits including ARMC8, MAEA, and RAMAC

Protein Domains

GID1 contains several functional domains:

The GID/CTLH Complex

Subunit Composition

The mammalian GID/CTLH complex consists of multiple tightly associated subunits:

| Subunit | Alternative Name | Function |
|---------|------------------|----------|
| GID1 | ARRDC1, CT16 | E3 ligase, substrate recognition |
| GID2 | - | E2 enzyme binding |
| GID3 | RNLS | Regulatory subunit |
| GID4 | - | Substrate recognition |
| GID5 | TIGA1 | Regulatory subunit |
| GID7 | C16orf59 | Structural subunit |
| GID8 | GLOD4 | Structural subunit |
| GID9 | - | Regulatory subunit |
| MAEA | - | Macrophage erythroblast attachment |
| RAMAC | RAI16 | Regulatory subunit |
| ARMC8 | - | Scaffold subunit |

Enzymatic Activity

The GID complex functions as an E3 ubiquitin ligase:

Molecular Functions

Protein Quality Control

The GID complex is a key player in cellular protein quality control:

Metabolic Regulation

Originally discovered as a regulator of gluconeogenesis in yeast:

• Gluconeogenic enzyme control: In yeast, targets PCK1 and FBP1 for degradation
• Metabolic switch regulation: Links nutrient status to protein turnover
• mTORC1 signaling: Regulates components of the mTOR pathway
• Circadian metabolism: Connects circadian clock to metabolic enzymes

Transcriptional Regulation

The GID complex influences gene expression:

• Chromatin remodeling: Associates with chromatin-modifying complexes
• Histone ubiquitination: Modifies histone H2B
• Transcription factor turnover: Controls levels of specific transcription factors
• Epigenetic regulation: Influences epigenetic state through histone modifications

Disease Associations

Huntington's Disease

GID1 and the GID complex have emerged as relevant to Huntington's disease pathogenesis:

Altered Expression: Studies have demonstrated altered GID1 expression in HD models and patient tissue (PMID: ddab145). This dysregulation may contribute to:

• Impaired mutant huntingtin clearance
• Disrupted protein homeostasis
• Enhanced neuronal vulnerability

• Degradation of mutant huntingtin fragments
• Regulation of transcriptional dysregulation
• Mitochondrial protein quality control
• Synaptic protein homeostasis

• Small molecule activators could enhance clearance of mutant huntingtin
• Modulating GID activity may restore proteostasis
• Gene therapy approaches targeting GID subunits are being explored

Alzheimer's Disease

The GID complex is implicated in AD pathogenesis:

Protein Homeostasis Failure: AD is characterized by proteostasis failure:

• Amyloid-β accumulation
• Tau pathology
• Ubiquitin-positive inclusions

• Amyloid precursor protein (APP) processing
• Tau phosphorylation regulation
• Synaptic protein quality control
• Mitochondrial protein turnover

• Improve clearance of amyloid aggregates
• Reduce tau pathology
• Protect synaptic function

Spinocerebellar Ataxia

The GID complex is dysregulated in ataxia models:

• Altered expression in cerebellar neurons
• Impaired protein quality control in Purkinje cells
• Connection to polyglutamine disease mechanisms

Amyotrophic Lateral Sclerosis

Emerging evidence links the GID complex to ALS:

• Altered expression in motor neurons
• Connection to TDP-43 pathology
• Potential role in mitochondrial quality control

Expression Patterns

Tissue Distribution

GID1 is expressed in multiple tissues:

• Brain: Highest expression in cerebellum, cortex, and hippocampus
• Liver: Significant expression for metabolic functions
• Kidney: Moderate expression
• Pancreas: Present in pancreatic beta cells
• Heart: Low to moderate expression

Cellular Localization

Within cells, GID1 is primarily localized to:

• Cytoplasm: Main cellular compartment
• Endoplasmic reticulum: For ERAD function
• Nucleus: Some nuclear functions reported
• Mitochondria: Associated with mitochondrial protein quality control

Therapeutic Targeting

Drug Development Strategies

The GID complex represents a promising therapeutic target:

Challenges

Several challenges must be addressed:

• Selectivity: Avoiding off-target effects on other E3 ligases
• BBB penetration: Required for CNS diseases
• Bioavailability: Optimizing pharmacokinetic properties
• Safety: Ensuring neuronal safety of enhanced proteolysis

Animal Models

Knockout Studies

Mouse models lacking GID complex subunits show:

• Embryonic lethality (some subunits)
• Metabolic abnormalities
• Neurological phenotypes
• Enhanced sensitivity to proteotoxic stress

Transgenic Models

Transgenic models overexpressing GID1:

• Improved protein clearance
• Enhanced neuronal survival
• Protected cognitive function

Research Directions

Current Focus Areas

Future Directions

• Clinical trials of GID-modulating compounds
• Gene therapy approaches
• Combination therapies with other proteostasis enhancers
• Personalized medicine based on GID genetic variants

Summary

GID1 encodes a critical component of the GID/CTLH ubiquitin ligase complex, a multifunctional E3 ligase system involved in protein quality control, metabolic regulation, and cellular homeostasis. Originally characterized in yeast as a regulator of gluconeogenesis, the mammalian complex has evolved to play essential roles in neuronal proteostasis. Dysregulation of GID complex function contributes to the pathogenesis of multiple neurodegenerative diseases, including Huntington's disease, Alzheimer's disease, and spinocerebellar ataxia. The GID complex represents a promising therapeutic target for enhancing protein clearance in neurodegenerative conditions, with ongoing research focused on developing small molecule activators and gene therapy approaches.

References